Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 224, Issue -, Pages S1-S21Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab305
Keywords
SARS-CoV-2; antiviral therapeutics; emerging modalities; preclinical; proteases; viral replication machinery
Categories
Funding
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences
- Office of the Director, National Institutes of Health, Bethesda, MD, United States
Ask authors/readers for more resources
The NIH Virtual SARS-CoV-2 Antiviral Summit aimed to provide an overview of the status and challenges in developing antiviral therapeutics for COVID-19, with the goals of reviewing the current science, sharing insights, and identifying opportunities for collaboration.
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available